WallStreetZenWallStreetZen

NYSE: ABBV
Abbvie Inc Earnings & Revenue

Open Broker Account
OverviewForecastEarnings
DividendOwnership

ABBV past earnings growth

How has ABBV's earnings growth performed historically?
Company
93.19%
Industry
53.02%
Market
53.18%
ABBV's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ABBV's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ABBV's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ABBV past revenue growth

How has ABBV's revenue growth performed historically?
Company
6.74%
Industry
19.06%
Market
113.02%
ABBV's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ABBV's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ABBV's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ABBV earnings and revenue history

Current Revenue
$57.3B
Current Earnings
$12.6B
Current Profit Margin
22%

ABBV Return on Equity

Current Company
84.4%
Current Industry
41.5%
Current Market
25.7%
ABBV's Return on Equity (84.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ABBV announces earnings.

ABBV Return on Assets

Current Company
8.7%
Current Industry
10.3%
ABBV is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ABBV Return on Capital Employed

Current Company
14.98%
Current Industry
15.9%
ABBV has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ABBV vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ABBV$57.35B$24.50B$12.64B+16.51%+11.58%
PFE$101.13B$37.05B$29.31B+14.08%+30.48%
MRK$57.17B$22.10B$16.58B+7.40%+28.81%
LLY$29.07B$7.84B$5.69B+5.73%+21.97%
AZN$44.04B$7.12B-$1.25B+15.16%N/A
View Top General Drug Manufacturer Stocks

ABBV earnings dates

Next earnings date
Oct 27, 2022

Abbvie Earnings & Revenue FAQ

What were ABBV's earnings last quarter?

On Invalid Date, Abbvie (NYSE: ABBV) reported Q2 2022 earnings per share (EPS) of $0.52, up 23.81% year over year. Total Abbvie earnings for the quarter were $924.00 million. In the same quarter last year, Abbvie's earnings per share (EPS) was $0.42.

If you're new to stock investing, here's how to buy Abbvie stock.

What was ABBV's earnings growth in the past year?

As of Q4 2022, Abbvie's earnings has grown 93.19% year over year. This is 40.17 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 53.02%. Abbvie's earnings in the past year totalled $12.64 billion.

What is ABBV's earnings date?

Abbvie's earnings date is Invalid Date. Add ABBV to your watchlist to be reminded of ABBV's next earnings announcement.

What was ABBV's revenue last quarter?

On Invalid Date, Abbvie (NYSE: ABBV) reported Q2 2022 revenue of $14.58 billion up 4.47% year over year. In the same quarter last year, Abbvie's revenue was $13.96 billion.

What was ABBV's revenue growth in the past year?

As of Q4 2022, Abbvie's revenue has grown 6.74% year over year. This is 12.33 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 19.06%. Abbvie's revenue in the past year totalled $57.35 billion.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market Industries
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.